Genetic Signatures Ltd
ASX:GSS
Intrinsic Value
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. [ Read More ]
The intrinsic value of one
GSS
stock under the Base Case scenario is
0.7
AUD.
Compared to the current market price of 0.76 AUD,
Genetic Signatures Ltd
is
Overvalued by 8%.
Genetic Signatures Ltd's market capitalization is 141.7m AUD.
GSS stock price is 0.76 AUD.
GSS stock (0.7 AUD) is 8% less than its price (0.76 AUD).
GSS's Revenue has dropped by 33% over the past 12 months.
GSS's ROE (Return on Equity) has significantly decreased in the last 3 years from 10% to -40%.
GSS's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 44% to -77%.
GSS's Revenue is forecast to grow at a rate of 33% per year over the next 3 years.
GSS's Revenue has been falling by 17% per year for the last 3 years.
GSS has negative Operating Income for the last twelve months.
GSS has negative Net Income for the last twelve months.
GSS's ROE (Return on Equity) for the past 12 months is negative and is equal to -40%.
GSS's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -77%.
GSS has positive Gross Profit for the last twelve months.
GSS has negative three-year average ROE (Return on Equity): -9%. The company is not efficient at transforming stockholders' equity into net income.
GSS has negative Free Cash Flow for the last twelve months.
GSS has negative three-year average ROIC (Return on Invested Capital): -13%. The company is not efficient at using invested capital to generate operating income.
GSS's short-term assets (31m AUD) exceed its short-term liabilties (4m AUD).
GSS's long-term assets (44m AUD) exceed its long-term liabilties (4m AUD).
GSS's D/E (Debt to Equity) is very low and is equal to 0.
GSS's Altman Z-Score is very high and is equal to 9.95.
Valuation Backtest
Genetic Signatures Ltd
Run backtest to discover the historical profit from buying and selling
GSS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Genetic Signatures Ltd
Balance Sheet Decomposition
Genetic Signatures Ltd
| Current Assets | 30.9m |
| Cash & Short-Term Investments | 18.1m |
| Receivables | 4.6m |
| Other Current Assets | 8.1m |
| Non-Current Assets | 13.6m |
| PP&E | 7.6m |
| Intangibles | 6m |
| Current Liabilities | 3.8m |
| Accounts Payable | 2.7m |
| Other Current Liabilities | 1.2m |
| Non-Current Liabilities | 124k |
| Other Non-Current Liabilities | 124k |
Earnings Waterfall
Genetic Signatures Ltd
|
Revenue
|
16.5m
AUD
|
|
Cost of Revenue
|
-9.8m
AUD
|
|
Gross Profit
|
6.7m
AUD
|
|
Operating Expenses
|
-24.7m
AUD
|
|
Operating Income
|
-18m
AUD
|
|
Other Expenses
|
-1k
AUD
|
|
Net Income
|
-18m
AUD
|
Free Cash Flow Analysis
Genetic Signatures Ltd
GSS Profitability Score
Profitability Due Diligence
Genetic Signatures Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Genetic Signatures Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
GSS Solvency Score
Solvency Due Diligence
Genetic Signatures Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Genetic Signatures Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GSS Price Targets Summary
Genetic Signatures Ltd
According to Wall Street analysts, the average 1-year price target for
GSS
is 0.77 AUD
with a low forecast of 0.76 AUD and a high forecast of 0.79 AUD.
Shareholder Return
GSS Price
Genetic Signatures Ltd
| Average Annual Return | 7.86% |
| Standard Deviation of Annual Returns | 63.56% |
| Max Drawdown | -86% |
| Market Capitalization | 141.7m AUD |
| Shares Outstanding | 186 523 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Genetic Signatures Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Genetic Signatures Ltd. engages in the research and commercialization of identifying individual genetic signatures to identify diseases and disabilities. The company is headquartered in Sydney, New South Wales. The company went IPO on 2015-03-31. The firm is engaged in research and commercialization of identifying individual genetic signatures to aid in the diagnosis of infectious diseases and the sale of associated products into the diagnostic and research marketplaces. The firm is focused on the development and commercialization of its platform technology, 3Base. The Company’s 3Base platform technology provides hospital and pathology laboratories the ability to screen for an array of infectious pathogens, with a degree of specificity, in a rapid throughput (time-to-result) environment. The company also manufactures a Polymerase Chain Reaction (PCR) based products for the detection of infectious diseases under the EasyScreen brand. The Company’s EasyScreen sample processing kits are used to perform 3Base conversion and nucleic acid extraction and purification.
Contact
IPO
Employees
Officers
The intrinsic value of one
GSS
stock under the Base Case scenario is
0.7
AUD.
Compared to the current market price of 0.76 AUD,
Genetic Signatures Ltd
is
Overvalued by 8%.
You don't have any saved screeners yet
